•Patient receives a low dose injection of a radiotracer (Tc-99m Sestamibi) by IV

•The tracer preferentially accumulates in cancer cells and is not influenced by breast density

•The breast is lightly immobilized between 2 digital gamma cameras, only light pain-free compression is necessary (1/3 of the pressure used in mammography)

• Imaging starts ~5 minutes post injection. Acquire CC and MLO views of each breast

•The patient is injected with Tc-99 Sestamibi

•The injection is in the contra-lateral  arm

•If there are suspicious areas in both breasts an injection in the foot is preferred

•The patient is imaged as soon as 5 minutes after injection • At 8mCi’s – 5 minute scanning per view

•At 4mCi’s – 10 minute scanning per view

•LumaGEM™ uses light compression (15 lbs of pressure as compared to 40-45 lbs used in mammography)

•Breast tissue simply needs to be immobilized

The Mayo Clinic

1,007 patient study shows:

•  91% Sensitivity

• 93% Specificity

Additional Clinical Parameters:

1.6 mm resolution v v

Energy resolution: 4.5% v v

Low Dose (4-8 mCi)

MBI Studies Published in April 2011 in Journal of Nuclear Medicine

The Mayo Clinic, Rochester, MN

Study: MBI’s Effectiveness in Pre-operative Evaluation of Women with Biopsy-Proven Breast Cancer

A total of 98 patients with biopsy-proven breast cancer were enrolled and underwent pre-operative MBI and completed surgical resection.

MBI detected additional disease greater than that identified by the combo of mammogram and ultrasound which altered surgical treatment in 12 patients (12/98 = 12.2%).

In 7 of 98 patients, MBI detected additional foci of cancer not seen on mammography (7.1%). This resulted in change of surgical treatment plan from breast conservation to mastectomy. Final pathology confirmed that mastectomy was warranted.

Conclusion: MBI can detect IDC, DCIS, and ILC, and can play a valuable role in evaluating extent of disease and presence of multifocal disease in the breast for surgical treatment planning.